Oncology Institute (TOI) Depreciation & Amortization (CF) (2021 - 2026)

Oncology Institute has reported Depreciation & Amortization (CF) for 6 years, with the latest figure at $1.6 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 9.42% year-over-year to $1.6 million; the trailing twelve-month figure through Mar 2026 stood at $6.8 million (up 2.95% YoY), and the FY2025 full-year result was $6.9 million, up 10.45% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $1.6 million, down from $1.6 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $1.8 million in Q2 2025, with the low at $987000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $1.5 million across 5 years, with a median of $1.6 million in 2024.
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) soared 49.74% — and 2026, when it fell 9.42%.
• Oncology Institute's Depreciation & Amortization (CF) stood at $1.2 million in 2022, then jumped by 32.3% to $1.6 million in 2023, then grew by 8.24% to $1.7 million in 2024, then declined by 4.39% to $1.6 million in 2025, then fell by 0.98% to $1.6 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.6 million (Q1 2026), $1.6 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.